

CS Pharmaceuticals Announces Inclusion of BRONCHITOL® in Beijing Tianzhu and Hainan Bo'ao Pilot Zones

London, England, August 28, 2025 – CS Pharmaceuticals Ltd. (CSP), a British clinical stage specialty pharmaceutical company focused on first- and best-in-class ocular therapeutics and treatments for rare diseases in China, together with its partner Arna Pharma, announced the approval and inclusion of BRONCHITOL® in the Beijing Tianzhu and Hainan Bo'ao pilot zones.

The inclusion of BRONCHITOL® in these pilot zones enables Chinese patients living with cystic fibrosis to access, for the first time, a globally approved pharmaceutical product specifically indicated for the treatment of this rare disease. Cystic fibrosis is listed in the Chinese Catalogue of Rare Diseases and BRONCHITOL® is recommended in the China cystic fibrosis diagnosis and treatment guideline. Cystic fibrosis remains a significantly under-recognised condition in China, with no previously approved pharmaceutical treatments available.

“We are delighted to announce the listing of BRONCHITOL® in the Beijing Tianzhu and Hainan Bo'ao pilot zones,” said Darren Mercer, Chief Executive Officer of CSP. “Cystic fibrosis is an underdiagnosed rare disease in China with devastating consequences. The underlying mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that cause Cystic Fibrosis differ between Chinese and Caucasian populations, meaning that correctors such as TRIKAFTA®/KAFTRIO® are likely to be ineffective in Chinese patients. Working closely with leading cystic fibrosis experts in China, CSP identified that the mechanism of action of BRONCHITOL® is conserved in Chinese patients, making it an ideal therapy for introduction via the pilot zones.”

About BRONCHITOL®

BRONCHITOL® is approved for the treatment of cystic fibrosis to help patients clear mucus from their lungs. It is a precision spray-dried form of mannitol delivered via a specially designed, portable inhaler. BRONCHITOL® works by rehydrating the airway surfaces and promoting a productive cough.

BRONCHITOL® has been evaluated in three large-scale clinical trials and is approved in over 30 countries, including the United States, Europe, the United Kingdom, and Australia. Clinical data have demonstrated that BRONCHITOL® helps to increase mucus clearance, improve lung function and the quality of life of people living with cystic fibrosis.

In China, BRONCHITOL® is now approved in several pilot zones. Cystic fibrosis, which is listed on the Chinese catalogue of rare diseases is a greatly under-recognised condition in China with no approved pharmaceutical products. BRONCHITOL® has been recommended in the China national cystic fibrosis diagnosis and treatment guideline.

About CS Pharmaceuticals

CSP is a global specialty pharmaceutical company with a rich heritage and expertise in developing and commercialising products. CSP's focus is on the development and commercialisation of



innovative ophthalmology, rare and speciality diseases to address high unmet medical needs and improve the lives of patients around the world.

CSP's global ophthalmology product, CSP-270, is for the treatment of Meibomian Gland Dysfunction. With excellent phase II clinical data, CSP-270 has the potential to be the first approved pharmaceutical product for MGD with forecasted sales potential of \$1.3 to 2.5 billion US dollars.

CSP's first licensed rare disease product for patients with Cystic Fibrosis is now approved in several pilot zones in China. Cystic fibrosis remains a significantly under-recognised condition in China with no approved pharmaceutical products.

CSP is leveraging its unique cross-border business model and strong reputation to establish strategic partnerships with more pharmaceutical companies both in the West and in China as it continues to expand its portfolio.

www.cspharmaceuticals.com

Contacts

CS Pharmaceuticals
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2038 573830

